Investor
As part of the deal, Aegis Ventures will pour $100 million in seed-stage funding into the effort.
Hinge said more than $1 billion has been invested in the company thus far.
At the beginning of October, Transcarent inked a deal with Walmart to lower prescription drugs.
The company said the Series D brings its total raise to $256 million.
Also: Anomaly scores $17 million for health payments, and Arine rakes in $11 million for medication management.
This new funding round brings the company's total raise to $521 million.
SonderMind said the purchase will help providers deliver personalized mental healthcare.
The company plans to use the funding to expand into new regions. It aims to operate nationwide by 2023.
The deal is expected to close by the end of 2021.
This news comes roughly a year after the company signed a $500 million deal with Boehringer Ingelheim.